



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 63/00, A61K 35/12, 35/30, C12N 1/00	A1	(11) International Publication Number: WO 97/09885 (43) International Publication Date: 20 March 1997 (20.03.97)
(21) International Application Number: PCT/US96/14578 (22) International Filing Date: 12 September 1996 (12.09.96) (30) Priority Data: 08/528,845 15 September 1995 (15.09.95) US 08/695,351 9 August 1996 (09.08.96) US (71) Applicant (for all designated States except US): YEDA RESEARCH AND DEVELOPMENT CO., LTD. [IL/IL]; P.O. Box 95, 76100 Rehovot (IL). (72) Inventors; and (75) Inventors/Applicants (for US only): EISENBACH-SCHWARTZ, Michal [IL/IL]; 5 Rupin Street, 76353 Rehovot (IL). SPIEGLER, Orly [IL/IL]; 11 Pinsky Street, 76308 Rehovot (IL). HIRSCHBERG, David, L. [US/IL]; Hanassi Harishon Street, 76308 Rehovot (IL). (74) Agents: BALDWIN, Geraldine, F. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: COMPOSITIONS AND METHODS OF USE OF MONONUCLEAR PHAGOCYTES TO PROMOTE AXONAL REGENERATION (57) Abstract Methods and compositions for the use of allogeneic mononuclear phagocytes to promote axonal regeneration in the central nervous system of a mammal are disclosed. In one embodiment, allogeneic mononuclear phagocytes are cultured together with stimulatory tissue, such as dermis or at least one nerve segment, and are subsequently administered into the central nervous system of a mammal at or near a site of injury or disease. In an alternative embodiment, autologous monocytes, preferably stimulated autologous monocytes, are administered into the central nervous system of a mammal at or near a site of injury or disease. Methods for identifying stimulatory tissue and cells and methods and compositions for cryopreserved allogeneic mononuclear phagocytes are also disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**COMPOSITIONS AND METHODS OF USE OF MONONUCLEAR
PHAGOCYTES TO PROMOTE AXONAL REGENERATION**

This is a continuation-in-part of co-pending application serial no. 08/528,845, filed September 15, 1995, the entire disclosure of which is incorporated herein by reference.

1. FIELD OF THE INVENTION

The present invention relates to compositions comprising mononuclear phagocytes, and to methods for using mononuclear phagocytes, to promote axonal regeneration in mammals affected by injury or disease of the central nervous system, as well as to compositions and methods for enhancing the therapeutic capacity of mononuclear phagocytes to promote axonal regeneration. In particular, the invention relates to (a) pharmaceutical compositions comprising, and methods for administering, stimulated or non-stimulated allogeneic mononuclear phagocytes at or near a site of the mammalian central nervous system affected by injury or disease to promote axonal regeneration, (b) compositions and methods for stimulating mononuclear phagocytes so as to enhance their capacity to promote axonal regeneration, and (c) methods for screening tissues, cells, proteins, peptides and other biologically active agents for their ability to stimulate mononuclear phagocytes for promoting axonal regeneration.

2. BACKGROUND OF THE INVENTION

Following axonal injury, neurons of the mammalian central nervous system (CNS) have a poor capacity for axonal regeneration. By contrast, neurons of the mammalian peripheral nervous system (PNS) have a substantially greater capacity for axonal regeneration. See Schwartz et al., 1989, FASEB J. 3:2371-2378.

The difference between axonal regeneration in the CNS and PNS has been attributed to the cellular environment of the neurons rather than to the neurons themselves. Following neuronal injury, the Schwann cells that surround PNS neurons are modulated so as to become permissive or supportive for

axonal regeneration. By contrast, the astrocytes, oligodendrocytes and microglia that surround CNS neurons do not show such modulation and remain unsupportive or inhibitory for axonal regeneration. See Schwartz et al., 5 1987, CRC Crit. Rev. Biochem. 22:89-110.

This lack of modulation has been correlated with differences in the post-injury inflammatory response. See Perry and Brown, 1992, Bioessays 14:401-406; Lotan and Schwartz, 1994, FASEB J. 8:1026-1033. In particular, the 10 accumulation of mononuclear phagocytes in response to CNS injury is delayed and limited in comparison with the response to injury in the PNS. This limited CNS mononuclear phagocyte response may in turn lead to (1) inefficient removal of the myelin debris that reportedly inhibits axonal regeneration, 15 and (2) suboptimal release of macrophage-derived cytokines that would promote modulation of astrocytes and oligodendrocytes so as to support axonal regeneration.

The above observations have prompted speculation that appropriate modulation of the macrophage response might 20 promote axonal regeneration after CNS injury. In an *in vitro* system, David et al. showed that when cryostat sections of normal rat optic nerve are co-cultured with mononuclear phagocytes derived from lesions of the rat CNS, the optic nerve sections show enhanced adhesiveness for embryonic chick 25 dorsal root ganglion cells. David et al., 1990, Neuron 5:463-469. Conditioned medium from activated peritoneal macrophages was also effective in promoting adhesiveness of optic nerve sections in this *in vitro* assay.

However, results derived from *in vivo* models of CNS 30 injury have revealed that some interventions that enhance the macrophage response to CNS injury do not result in enhanced regeneration. For instance, local injection of either tumor necrosis factor alpha (TNF- α) or colony stimulating factor-1 (CSF-1) enhanced the macrophage response to experimental 35 optic nerve injury. However, only TNF- α , but not CSF-1, increased the permissiveness of the injured optic nerves for neuronal adhesion as assayed *in vitro*. Lotan et al., 1984,

Exp. Neurol. 126:284-290. It has been suggested as one possible explanation that "only appropriately stimulated macrophages can influence neuronal regeneration." Schwartz et al., 1994, Progress Brain Res. 103:331-341, at 338.

5 In fact, contrary to the teaching of the present invention, other investigators have reported that mononuclear phagocytes might exacerbate damage or limit recovery following CNS injury. Brain macrophages, when stimulated by cytokines, exhibit neurotoxic activity. Chamak et al., 1994,
10 J. Neurosci. Res. 38:221-233. Pharmacological inhibition of mononuclear phagocyte function has been reported to promote recovery in a rabbit model of spinal cord injury. Giulian and Robertson, 1990, Annals Neurol. 27:33-42. It has been suggested that macrophage-derived cytokines may promote
15 formation of glial scars and thereby inhibit axonal regeneration. Khan and Wigley, 1994, NeuroReport 5:1381-1385; Vick et al., 1992, J. Neurotrauma 9:S93-S103.

To the best knowledge of the present inventors, prior to the present invention there has been no suggestion to
20 administer mononuclear phagocytes into the CNS in order to promote axonal regeneration in the CNS.

Citation or identification of any reference in Section 2 (or any other section) of this application shall not be construed as an admission that such reference is available as
25 prior art to the present invention.

3. SUMMARY OF THE INVENTION

The present invention is directed to methods, and compositions, for use of allogeneic mononuclear phagocytes to
30 promote axonal regeneration in the central nervous system of a mammal. The allogeneic mononuclear phagocytes are administered into the CNS at or near a site of injury or disease.

Allogeneic mononuclear phagocytes useful for the methods
35 and compositions of the invention include, but are not limited to, allogeneic monocytes, macrophages and dendritic

cells, and autologous monocytes, macrophages and dendritic cells.

The present invention further provides methods, and compositions, for stimulating allogeneic mononuclear
5 phagocytes so as to enhance their capacity to promote axonal regeneration, and methods, and compositions, for use of stimulated allogeneic mononuclear phagocytes to promote axonal regeneration in the central nervous system of a mammal. The mononuclear phagocytes are stimulated by
10 culturing them together with suitable tissue or suitable cells, or by culturing the mononuclear phagocytes in medium that has been conditioned by suitable tissue or suitable cells. Tissues suitable for this purpose include, without limitation, nerve segments, especially segments of peripheral
15 nerve, dermis, synovial tissue, tendon sheath, liver, and other regenerating tissues. Alternatively, the mononuclear phagocytes are stimulated by culturing them in medium to which at least one suitable biologically active agent has been added. Biologically active agents suitable for this
20 purpose include, without limitation, neuropeptides; cytokines, for instance transforming growth factor- β (TGF- β); and neurotrophic factors, for instance neurotrophic factor 3 (NT-3), nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). A biologically active protein or
25 peptide may be used in its native or recombinant form.

Moreover, the present invention provides an assay for identifying additional tissues, cells and biologically active agents that are suitable for stimulating mononuclear phagocytes to enhance their capacity to promote axonal
30 regeneration. According to this assay, mononuclear phagocytes are first cultured together with the tissue or cells to be tested, or in medium that has been conditioned by the tissue or cells to be tested or in medium to which has been added the biologically active agent to be tested. The
35 phagocytic activity of the cultured mononuclear phagocytes is then measured. Mononuclear phagocytes with increased

phagocytic activity have an enhanced capacity to promote axonal regeneration.

4. BRIEF DESCRIPTION OF THE FIGURES

5 The present invention may be more fully understood by reference to the following detailed description of the invention, examples of specific embodiments of the invention and the appended figures in which:

FIGURE 1 illustrates axonal regeneration in transected
10 optic nerves of rats as detected by retrograde transport of fluorescent dye to retinal ganglion cells (RGCs). See text, Section 6, for experimental details. Shortly after transection, 2 μ l of DCCM-1 medium were applied to the site of injury containing no cells (MED); 2.5×10^3 - 1×10^5 non-
15 stimulated (NS) monocytes; 2.5×10^3 - 1×10^5 optic nerve-stimulated (OS) monocytes; or 2.5×10^3 - 1×10^5 sciatic nerve-stimulated (SS) monocytes. Open circles represent individual experimental animals. Solid circles represent animals that showed no labeled RGCs (numbering 7, 7 and 6 in
20 the MED, NS and OS treatment groups respectively). Horizontal lines represent the median value of each treatment group.

FIGURE 2 illustrates axonal regeneration in transected optic nerves of rats as a function of the number and type of
25 monocytes applied to the site of injury shortly after transection. See text, Section 6, for experimental details. At the time of transection, 2 μ l DCCM-1 medium were applied to the site of injury containing optic nerve-stimulated monocytes (OS) or sciatic nerve-stimulated monocytes (SS) at
30 a total dose of 2.5×10^3 cells; 5×10^3 cells; 10^4 cells; or 10^5 cells.

FIGURE 3 (A-B) presents representative photomicrographs showing retrograde labeling of retinal ganglion cells in rats subjected to optic nerve transection followed by
35 administration of (A) 5×10^3 sciatic nerve-stimulated monocytes or (B) control medium. See text, Section 6, for experimental details.

FIGURE 4 (A-E) presents representative photomicrographs showing anterograde labeling of optic nerve fibers in rats subjected to optic nerve transection followed by administration of sciatic nerve-stimulated monocytes (A-D) or control medium (E). See text, Section 6, for experimental details. FIGURE 4A is a low magnification view showing the point at which HRP was applied (H), the site of transection (ST) and the surrounding dura mater (DU). The bracketed region, distal to the site of transection, is shown at higher magnification in FIGURES 4B, 4C and 4D, in which growth cone-like structures (gc) are shown at the tips of the fibers.

FIGURE 5 illustrates axonal regeneration in transected optic nerves of rats after application to the site of injury of monocytes cultured with sciatic nerve for 2-17 hours. See text, Section 6, for experimental details. At the time of transection, 2 μ l of DCCM-1 medium were applied to the site of injury containing 5×10^3 non-stimulated monocytes (NS) or 5×10^3 monocytes cultured with rat sciatic nerve for 2 hours (2h), 12 hours (12h) or 17 hours (17h).

FIGURE 6 illustrates axonal regeneration in transected optic nerves after administration, at the site of injury, of rat monocytes stimulated with mouse sciatic nerve or rat sciatic nerve. See text, Section 6, for experimental details. At the time of transection, 2 μ l DCCM-1 medium were applied to the site of injury containing 5×10^3 monocytes cultured for 24 hours with either mouse sciatic nerve (MOUSE) or rat sciatic nerve (RAT).

FIGURE 7 illustrates the phagocytic activity of rat monocytes cultured for 2 hours with rat sciatic nerve. See text, Section 6, for experimental details. 2.5×10^5 rat monocytes were cultured in 1 ml DCCM-1 medium alone (CONTROL) or in 1 ml DCCM-1 medium with 2 segments of rat sciatic nerve (2SS) or with 4 segments of rat sciatic nerve (4SS). After 2 hours, the monocytes were exposed to fluorescent beads and cell-associated fluorescence was measured by flow cytometry.

FIGURE 8 illustrates the phagocytic activity of rat monocytes cultured for 24 hours with rat sciatic nerve. See

text, Section 6, for experimental details. 2.5×10^5 rat monocytes were cultured in 1 ml DCCM-1 medium alone (CONTROL) or in 1 ml DCCM-1 medium with 1 segment of rat sciatic nerve (1SS) or with 4 segments of rat sciatic nerve (4SS). After 5 16-24 hours, the monocytes were exposed to fluorescent beads and cell-associated fluorescence was measured by flow cytometry.

FIGURE 9 illustrates the phagocytic activity of rat monocytes cultured for 2 hours with rat optic nerve. See 10 text, Section 6, for experimental details. 2.5×10^5 rat monocytes were cultured in 1 ml DCCM-1 medium alone (CONTROL) or in 1 ml DCCM-1 medium with 4 segments of rat optic nerve (4OS). After 2 hours, the monocytes were exposed to fluorescent beads and cell-associated fluorescence was 15 measured by flow cytometry.

FIGURE 10 illustrates the phagocytic activity of rat monocytes cultured for 24 hours with rat optic nerve. See text, Section 6, for experimental details. 2.5×10^5 rat monocytes were cultured in 1 ml DCCM-1 medium alone (CONTROL) 20 or in 1 ml DCCM-1 medium with 4 segments of rat optic nerve (4OS). After 24 hours, the monocytes were exposed to fluorescent beads and cell-associated fluorescence was measured by flow cytometry.

FIGURE 11 illustrates the phagocytic activity of rat 25 monocytes cultured overnight with rat sciatic nerve in the presence of medium conditioned by rat optic nerve. 5×10^5 rat monocytes were cultured in 1 ml DCCM-1 medium with 6 segments of rat sciatic nerve with no further additions (0) or with the addition of optic nerve-conditioned medium at a 30 total protein concentration of $0.1 \mu\text{g/ml}$ (0.1), $1.0 \mu\text{g/ml}$ (1), or $10 \mu\text{g/ml}$ (10). After 24 hours, the monocytes were exposed to fluorescent beads and cell-associated fluorescence was measured by flow cytometry.

5. DETAILED DESCRIPTION OF THE INVENTION

5.1 MONONUCLEAR PHAGOCYTES

The present invention provides methods, and compositions, for use of allogeneic mononuclear phagocytes to promote axonal regeneration following injury or disease of the central nervous system (CNS). The allogeneic mononuclear phagocytes are introduced at or near the site of CNS injury or disease.

As used herein, the term "mononuclear phagocytes" is intended to comprise, without limitation, monocytes obtained from central or peripheral blood, macrophages obtained from any site, including any tissue or cavity, macrophages derived by culturing macrophage precursors obtained from bone marrow or blood, dendritic cells obtained from any site, including spleen, lymph node, skin and lymphatic fluid, and dendritic cells derived from culturing dendritic cell precursors obtained from bone marrow or blood.

Allogeneic mononuclear phagocytes can be obtained from the circulation or from any tissue in which they reside. Peripheral blood is an easily accessible ready source of allogeneic monocytes and is used as a source according to a preferred embodiment of the invention. Especially preferred is the use of autologous monocytes purified from the peripheral blood of a subject to whom the therapeutic preparation is intended to be administered.

Allogeneic mononuclear phagocytes from other sources are well known in the art and include, without limitation, macrophages obtained from serosal cavities such as the peritoneal or pleural cavity, alveolar macrophages, and macrophages associated with other tissues, where they may be known by various terms such as Kupffer cells (in the liver) and microglial cells (in the CNS). Allogeneic mononuclear phagocytes further include dendritic cells, which likewise may be known by various terms, such as Langerhans cells (in the skin), veiled cells (in lymphatic fluid) and interdigitating cells (in lymph nodes). Additionally mononuclear phagocytes can be derived by culture from

allogeneic brain-derived mixed glial cells or from allogeneic precursor cells, which may be obtained from bone-marrow or blood.

In a preferred embodiment, cells other than mononuclear
5 phagocytes are depleted from the cell population to be administered. Enrichment techniques are well known to those skilled in the art and include, without limitation, elutriation; centrifugation through material of suitable density, such as a Percoll gradient (Colotta et al., 1983, J.
10 Immunol. 132:936-944); selective adhesion on suitable surfaces followed by removal at reduced temperature or at reduced concentrations of divalent cations (Rosen and Gordon, 1987, J. Exp. Med. 166:1685-1701), mechanical removal, or removal in the presence of lidocaine; and techniques for
15 isolating dendritic cells from blood (O'Doherty et al., 1993, J. Exp. Med. 178:1067-1078), bone marrow (Inaba et al., 1992, J. Exp. Med. 176:1693-1702) and lymphoid tissue (Macatonia et al., J. Exp. Med. 169:1255-1264). Especially preferred is a substantially purified preparation of mononuclear phagocytes.

20 Once the mononuclear phagocytes are obtained they may be used therapeutically at any desired time, according to the needs of the patient. The mononuclear phagocytes may, if desired, be cultured prior to administration in any suitable culture medium. Preferably, the mononuclear phagocytes are
25 cultured in a vessel made from sterile material to which these cells show limited or no adherence. In a preferred embodiment, the mononuclear phagocytes are cultured in sterile Teflon bags prior to administration.

As used herein, "stimulated" mononuclear phagocytes are
30 mononuclear phagocytes with an enhanced capacity to promote axonal regeneration. Preferably, the capacity of the mononuclear phagocytes to promote axonal regeneration is enhanced at least three-fold over non-stimulated mononuclear phagocytes, more preferably the capacity of the mononuclear
35 phagocytes to promote axonal regeneration is enhanced at least 15-fold over non-stimulated mononuclear phagocytes. "Stimulatory" tissue, cells and biologically active agents

are tissue, cells and biologically active agents that, when cultured together with mononuclear phagocytes, enhance the capacity of the mononuclear phagocytes to promote axonal regeneration.

5 In a preferred embodiment, stimulatory tissue, cells or at least one stimulatory biologically active agent is added to the culture in order to enhance the capacity of the mononuclear phagocytes to promote axonal regeneration. Preferably, one or more segments of a nerve, most preferably
10 a peripheral nerve such as the sciatic nerve, are added to the culture. A xenogeneic nerve is suitable for this purpose or, more preferably, an allogeneic or autologous nerve. If desired, a human nerve can be obtained from any available human tissue, such as a human cadaver or a surgical specimen
15 (e.g. an amputated limb). Alternatively other stimulatory tissue or cells are added to the culture. Dermis is suitable for this purpose and can be obtained, from a living donor or a cadaver, by punch biopsy, by surgical resection, or by any other suitable technique. Synovial tissue, tendon sheath and
20 liver are also suitable for this purpose, as are other regenerating tissues. Additional stimulatory tissues and cells can be identified according to the assay described below. If desired, the stimulatory tissue or cells are homogenized before addition to the culture. As will be
25 evident to those skilled in the art, the stimulatory tissue or cell homogenate can be preserved, e.g. by cryopreservation, before use.

In an alternative embodiment, at least one stimulatory biologically active agent is added to the culture in order to
30 enhance the capacity of the mononuclear phagocytes to promote axonal regeneration. Neurotrophic factor 3 (NT3), nerve growth factor (NGF), brain-derived neurotrophic factor and transforming growth factor- β (TGF- β) are suitable for this purpose either singly or in combination, whether in native or
35 recombinant form. Additional stimulatory biologically active agents (including additional stimulatory proteins and

peptides) can be identified according to the assay described below.

Preferably, the mononuclear phagocytes are cultured together with stimulatory tissue, stimulatory cells, 5 homogenate of stimulatory tissue or stimulatory cells, or at least one stimulatory biologically active agent for 24 hours. Shorter periods of culture, such as approximately 2 hours, are also effective, as are longer periods of culture, such as one or more weeks. In an alternative embodiment, stimulatory 10 conditioned medium is prepared by incubating stimulatory tissue or cells, preferably one or more segments of a nerve, most preferably a peripheral nerve such as the sciatic nerve, in any medium that is suitable for culturing mononuclear phagocytes. After removal of the tissue or cells, 15 mononuclear phagocytes are cultured in the stimulatory conditioned medium in order to enhance their capacity to promote axonal regeneration. After removal of the tissue or cells, the stimulatory conditioned medium can be stored and later used as desired for stimulating mononuclear phagocytes. 20 Such stimulatory conditioned medium can be provided in the form of a commercial kit. Preferably, the stimulatory conditioned medium is preserved during storage, for instance by refrigeration, whether as a liquid or as frozen medium. Alternatively, the stimulatory conditioned medium is 25 lyophilized.

As will be evident to those skilled in the art, the mononuclear phagocytes can be preserved, e.g. by cryopreservation, either before or after culture.

Cryopreservation agents which can be used include but 30 are not limited to dimethyl sulfoxide (DMSO) (Lovelock and Bishop, 1959, Nature 183:1394-1395; Ashwood-Smith, 1961, Nature 190:1204-1205), glycerol, polyvinylpyrrolidone (Rinfret, 1960, Ann. N.Y. Acad. Sci. 85:576), polyethylene glycol (Sloviter and Ravdin, 1962, Nature 196:548), albumin, 35 dextran, sucrose, ethylene glycol, i-erythritol, D-ribitol, D-mannitol (Rowe et al., 1962, Fed. Proc. 21:157), D-sorbitol, i-inositol, D-lactose, choline chloride (Bender

et al., 1960, J. Appl. Physiol. 15:520), amino acids (Phan The Tran and Bender, 1960, Exp. Cell Res. 20:651), methanol, acetamide, glycerol monoacetate (Lovelock, 1954, Biochem. J. 56:265), inorganic salts (Phan The Tran and Bender, 1960, 5 Proc. Soc. Exp. Biol. Med. 104:388; Phan The Tran and Bender, 1961, in Radiobiology, Proceedings of the Third Australian Conference on Radiobiology, Ilbery, P.L.T., ed., Butterworth, London, p. 59), and DMSO combined with hydroxyethyl starch and human serum albumin (Zaroulis and Leiderman, 1980, 10 Cryobiology 17:311-317).

A controlled cooling rate is critical. Different cryoprotective agents (Rapatz et al., 1968, Cryobiology 5(1):18-25) and different cell types have different optimal cooling rates. See, e.g., Rowe and Rinfret, 1962, Blood 15 20:636; Rowe, 1966, Cryobiology 3(1):12-18; Lewis et al., 1967, Transfusion 7(1):17-32; and Mazur, 1970, Science 168:939-949 for effects of cooling velocity on survival of marrow-stem cells and on their transplantation potential. The heat of fusion phase where water turns to ice should be 20 minimal. The cooling procedure can be carried out by use of, e.g., a programmable freezing device or a methanol bath procedure.

Programmable freezing apparatuses allow determination of optimal cooling rates and facilitate standard reproducible 25 cooling. Programmable controlled-rate freezers such as Cryomed or Planar permit tuning of the freezing regimen to the desired cooling rate curve.

After thorough freezing, cells can be rapidly transferred to a long-term cryogenic storage vessel. In one 30 embodiment, samples can be cryogenically stored in mechanical freezers, such as freezers that maintain a temperature of about -80°C or about -20°C. In a preferred embodiment, samples can be cryogenically stored in liquid nitrogen (-196°C) or its vapor. Such storage is greatly facilitated 35 by the availability of highly efficient liquid nitrogen refrigerators, which resemble large Thermos containers with an extremely low vacuum and internal super insulation, such

that heat leakage and nitrogen losses are kept to an absolute minimum.

Considerations and procedures for the manipulation, cryopreservation, and long term storage of hematopoietic stem
5 cells, particularly from bone marrow or peripheral blood, are largely applicable to the mononuclear phagocytes of the invention. Such a discussion can be found, for example, in the following references, incorporated by reference herein: Gorin, 1986, Clinics in Haematology 15(1):19-48; Bone-Marrow
10 Conservation, Culture and Transplantation, Proceedings of a Panel, Moscow, July 22-26, 1968, International Atomic Energy Agency, Vienna, pp. 107-186.

Other methods of cryopreservation of viable cells, or modifications thereof, are available and envisioned for use,
15 e.g., cold metal-mirror techniques. See Livesey and Linner, 1987, Nature 327:255; Linner et al., 1986, J. Histochem. Cytochem. 34(9):1123-1135; see also U.S. Patent No. 4,199,022 by Senken et al., U.S. Patent No. 3,753,357 by Schwartz, U.S. Patent No. 4,559,298 by Fahy.

20 Frozen cells are preferably thawed quickly (e.g., in a water bath maintained at 37-41°C) and chilled immediately upon thawing. It may be desirable to treat the cells in order to prevent cellular clumping upon thawing. To prevent clumping, various procedures can be used, including but not
25 limited to the addition before and/or after freezing of DNase (Spitzer et al., 1980, Cancer 45:3075-3085), low molecular weight dextran and citrate, hydroxyethyl starch (Stiff et al., 1983, Cryobiology 20:17-24), or acid citrate dextrose (Zaroulis and Leiderman, 1980, Cryobiology 17:311-317), etc.

30 The cryoprotective agent, if toxic in humans, should be removed prior to therapeutic use of the thawed mononuclear phagocytes. One way in which to remove the cryoprotective agent is by dilution to an insignificant concentration.

Once frozen mononuclear phagocytes have been thawed and
35 recovered, they are used to promote axonal regeneration as described herein with respect to non-frozen mononuclear phagocytes.

5.2 METHODS OF USE

According to the present invention, the mononuclear phagocytes are suspended in a sterile pharmaceutically acceptable carrier and administered into the CNS of a mammal, including a human subject, at or near a site of injury or disease.

In a preferred embodiment, the pharmaceutically acceptable carrier is PBS or a culture medium. However, alternative pharmaceutically acceptable carriers will readily be apparent to those skilled in the art.

In a preferred embodiment, the mononuclear phagocytes are administered immediately following CNS injury and are introduced at the site of CNS injury, for example with a glass micropipette. However, the present invention encompasses administration of mononuclear phagocytes at any time following CNS injury or disease and encompasses introduction of the mononuclear phagocytes at or near a site of CNS injury or disease by any neurosurgically suitable technique.

The compositions and methods of the present invention are useful for treating any injury or disease of the CNS that results in or is accompanied by axonal damage. The injury or disease may be situated in any portion of the CNS, including the brain, spinal cord, or optic nerve. One example of such injury or disease is trauma, including coup or countercoup injury, penetrating trauma, and trauma sustained during a neurosurgical operation or other procedure. Another example of such injury or disease is stroke, including hemorrhagic stroke and ischemic stroke. Yet another example of such injury or disease is optic nerve injury accompanying optic neuropathy or glaucoma. Still further examples of CNS injury or disease will be evident to those skilled in the art from this description and are encompassed by the present invention. The compositions and methods of the present invention are useful for treating CNS injury or disease that results in axonal damage whether or not the subject also suffers from other disease of the central or peripheral

nervous system, such as neurological disease of genetic, metabolic, toxic, nutritional, infective or autoimmune origin.

The optimal dose of mononuclear phagocytes is proportional to the number of nerve fibers affected by CNS injury or disease at the site being treated. In a preferred embodiment, the dose ranges from about 2.5×10^3 to about 10^5 mononuclear phagocytes for treating a lesion affecting about 10^5 nerve fibers, such as a complete transection of a rat optic nerve, and ranges from about 2.5×10^4 to about 10^6 mononuclear phagocytes for treating a lesion affecting about 10^6 nerve fibers, such as a complete transection of a human optic nerve. More preferably, the dose ranges from about 2.5×10^3 to about 5×10^4 mononuclear phagocytes for treating a lesion affecting about 10^5 nerve fibers and ranges from about 2.5×10^4 mononuclear phagocytes to about 5×10^5 mononuclear phagocytes for treating a lesion affecting about 10^6 nerve fibers. Especially preferred is a dose of about 5×10^3 mononuclear phagocytes for treating a lesion affecting about 10^5 nerve fibers and a dose of about 5×10^4 mononuclear phagocytes for treating a lesion affecting about 10^6 nerve fibers.

5.3 ASSAY FOR STIMULATORY TISSUES, CELLS AND BIOLOGICALLY ACTIVE AGENTS

The present invention provides an assay for identifying stimulatory tissues and cells and stimulatory biologically active agents. Mononuclear phagocytes are cultured together with the tissue or cells to be tested, in medium conditioned by the tissue or cells to be tested, or in medium to which the biologically active agent or agents to be tested have been added at various concentrations. Thereafter, the phagocytic activity of the mononuclear phagocytes is measured. Mononuclear phagocytes with increased phagocytic activity have an enhanced capacity to promote axonal regeneration. Preferably, the phagocytic capacity of the mononuclear phagocytes is increased by at least 10 percent,

more preferably by at least 25 percent, still more preferably by at least 50 percent.

In one embodiment, phagocytic activity is measured by contacting the mononuclear phagocytes with labeled particles 5 and subsequently determining the amount of label associated with the cells. A wide variety of particles can be used for this purpose, including without limitation latex or polystyrene beads and naturally occurring cells, such as red blood cells, yeast and bacteria. Optionally, the particles 10 can be opsonized, for instance with immunoglobulin or complement. The particles can be labeled with any suitable marker, including without limitation a fluorescent marker (such as fluorescein or rhodamine), a radioactive marker (such as a radioactive isotope of iodine, carbon or 15 hydrogen), and an enzyme. Alternatively, the assay can be performed with unlabeled particles (e.g. red blood cells or yeast); the unlabeled particles are detected by any suitable method, such as microscopically, with or without staining. In a preferred embodiment, the mononuclear phagocytes are 20 first contacted with fluorescent polystyrene beads; cell-associated fluorescence is subsequently measured by flow cytometry.

The assay of the present invention also provides a means of determining the period of culture required in order to 25 stimulate the mononuclear phagocytes. Mononuclear phagocytes are cultured for various periods with stimulatory tissue or cells, in medium conditioned by stimulatory tissue or cells, or in medium to which at least one stimulatory biologically active agent has been added. Thereafter, the phagocytic 30 activity of the mononuclear phagocytes is measured. A period of culture sufficient to increase the phagocytic activity of the mononuclear phagocytes by at least 10 percent, preferably by at least 25 percent, more preferably by at least 50 percent, is sufficient to stimulate their capacity to enhance 35 axonal regeneration.

The following examples are presented for purposes of

illustration only and are not intended to limit the scope of the invention in any way.

6. EXAMPLE: USE OF MONOCYTES TO PROMOTE AXONAL REGENERATION

5 6.1 MATERIALS AND METHODS

6.1.1 ISOLATION AND CULTURE OF MONOCYTES

Peripheral blood was pooled from adult Sprague-Dawley (SPD) rats. Monocytes were isolated by fractionation on a one-step Percoll gradient as previously described. F. Colotta
10 et al., 1984, J. Immunol. 132:936-944. The monocyte-enriched fraction was recovered from the Percoll interface, washed once with PBS to remove traces of Percoll, and resuspended at 1×10^6 cells/ml in DCCM-1 medium (Beit Ha'emek Ltd., Kibbutz Beit Ha'emek, Israel). The cells were cultured
15 in Teflon bags at 37°C as previously described. Andreessen et al., 1983, J. Immunolog. Meth. 56:295-304. Usually, each bag received 10 ml containing 1×10^6 cells.

6.1.2 STIMULATION OF MONOCYTES

20 Non-stimulated monocytes (NS) were prepared by culturing isolated monocytes in a Teflon bag, as described above, for 2-24 hours. Sciatic nerve-stimulated monocytes (SS) were prepared by culturing monocytes in a Teflon bag for 2-24 hours together with at least one segment of a rat sciatic
25 nerve. Optic nerve-stimulated monocytes (OS) were prepared by culturing monocytes in a Teflon bag for 2-24 hours together with at least one segment of a rat optic nerve. Each nerve segment was 1.0 - 1.5 cm long in experiments 6.2.1 and 6.2.2, and was 0.5 - 1.0 cm long in experiments 6.2.3 to
30 6.2.7; a constant ratio of 1 nerve segment to 5×10^6 cultured monocytes was used, except where otherwise noted.

After 2-24 hours in culture, monocytes were centrifuged for 3 minutes at 1000 x g, washed once with phosphate buffered saline (PBS), and resuspended in DCCM-1 medium at
35 1.25×10^6 - 5×10^6 cells/ml. The monocytes were 95% pure as determined by morphology and by immunocytochemistry with the

monoclonal antibody ED1 (Serotec, Oxford, England) as described. Hirschberg et al., 1994, J. Neuroimmunol. 50:9-16

6.1.3 OPTIC NERVE TRANSECTION

5 Anesthetized adult SPD rats, 8-9 weeks old, were subjected to optic nerve transection as described. Eitan et al., 1994, Science 264:1764-1768. The left optic nerve was exposed through a small opening in the meninges. A curved glass dissector with a 200 μ m tip and a smooth blunt edge was
10 moved across the nerve to create a complete transection 2-3 mm distal to the optic globe, taking care not to damage the peripheral blood vessels. As used herein, the term "distal" means away from the optic globe and towards the brain. Shortly after transection, 2 μ l of medium containing cultured
15 monocytes or 2 μ l of medium alone were introduced at the site of injury by means of a curved glass micropipette with a 25 μ m lumen. The meningeal opening was made about 200 μ m from the site of transection, in order to minimize leakage of cells from the site of application.

20

6.1.4 ASSAYS FOR AXONAL REGENERATION

6.1.4.1 RETROGRADE LABELING OF AXONS

Seven to eight weeks following transection, the lipophilic neurotracer dye, 4-(4-(didecylamino)styryl)-N-
25 methylpyridinium iodide (4Di-10ASP) (Molecular Probes, Eugene, Oregon, USA) was applied to the injured optic nerve, 2 mm distal to the site of injury. One week after application of the dye, the retina was removed, prepared as a flattened whole mount in 4% paraformaldehyde solution, and
30 examined by fluorescence microscopy to detect and count the number of labeled retinal ganglion cells (RGCs) in the entire retina. Only axons that had regrown past the site of injury to the site at which dye was applied could take up the dye and transport it retrogradely to the retinal ganglion cells.

35 When applied to rat optic nerves that have not previously been transected, this procedure labels an average of 21,623 RGCs per retina. The results for optic nerves that

were subjected to transection are expressed as a percentage of this standard, to control for the efficiency of the 4Di-10ASP labeling technique.

5

6.1.4.2 ANTEROGRADE LABELING OF AXONS

Seven to eight weeks following transection, a fresh incision was made in the previously transected optic nerve 1 mm proximal to the site of transection. As used herein, "proximal" means towards the optic globe and away from the brain. Horseradish peroxidase (HRP) (type VI-A, Sigma, Tel Aviv, Israel) was introduced through the incision by means of a sterile swab soaked in a 50% (w/v) solution of HRP in PBS. Eight to twelve hours after application of the HRP, the rats were perfused through the carotid artery with PBS followed by 4% paraformaldehyde in PBS as a fixative. The optic nerves were excised, 50 μ m longitudinal cryosections were taken and processed for visualization of HRP activity using diaminobenzidine and cobalt intensification as described. Lavie et al., 1992, Brain Res. 575:1-5.

20

6.1.5 ASSAY OF PHAGOCYTIC ACTIVITY

Rat monocytes were suspended in DCCM-1 medium (2.5×10^5 cells in 1 ml) and were cultured without further additions or together with the indicated number of rat sciatic or optic nerve segments. To assay phagocytic activity, a working solution of fluorescent noncarboxylated microspheres ("FLUORESBRITE"TM, Polysciences, Warrington, Pennsylvania, USA, Catalog. No. 17152) was prepared by diluting 1 drop of a stock solution in 10 ml DCCM-1 medium and adding this working solution to the monocyte suspension at a further dilution of 1:100. After three hours at 37°C, the cells were washed once with DCCM-1 medium or with phosphate-buffered saline, and cell-associated fluorescence was measured by flow cytometry (FACS).

35

6.2 RESULTS

6.2.1 PROMOTION OF AXONAL REGENERATION BY STIMULATED AND NON-STIMULATED MONOCYTES

Rats were subjected to optic nerve transection and
5 treated at the time of injury with control medium or with 2.5×10^3 - 1×10^5 non-stimulated (NS) monocytes, 2.5×10^3 - 1×10^5 sciatic nerve-stimulated (SS) monocytes, or 2.5×10^3 - 1×10^5 optic nerve-stimulated (OS) monocytes.

The number of labeled retinal ganglion cells (RGCs) in
10 rats from each treatment group is shown in Figure 1 as a percentage of RGCs labeled in normal optic nerves. Rats receiving no cells showed almost no labeling of RGCs. Rats receiving NS monocytes showed labeling of modest numbers of RGCs, while treatment with OS monocytes resulted in labeling
15 of greater numbers of RGCs. In rats receiving SS monocytes, the median number of labeled RGCs was over 5-fold higher than in the rats treated with OS monocytes, and was about 15-fold higher than in the rats treated with NS monocytes.

20 6.2.2 AXONAL REGENERATION AFTER TREATMENT WITH VARIOUS DOSES OF SCIATIC NERVE- OR OPTIC NERVE-STIMULATED MONOCYTES

To study regeneration as a function of the dose of
monocytes administered, rats were subjected to optic nerve
transection and treated at the time of injury with OS
25 monocytes or SS monocytes at a total dose of 2.5×10^3 ; 5×10^3 ; 1×10^4 ; or 1×10^5 cells.

The average number of labeled retinal RGCs in each
treatment group is shown in Figure 2 as a percentage of RGCs
labeled in normal optic nerves. RGC labeling was highest
30 after treatment with 5×10^3 SS monocytes. Higher or lower doses of SS monocytes promoted axonal regeneration but were less effective. Treatment with OS monocytes similarly promoted axonal regeneration, though less effectively. The peak effect, with both OS and SS monocytes, occurred at a
35 dose of 5×10^3 monocytes; at higher or lower doses the beneficial effect on axonal regeneration was less marked.

Representative fluorescence micrographs of labeled RGCs in retinas after treatment with SS monocytes or control medium are shown in Figure 3. The absence of labeled RGCs following treatment with control medium indicates that
5 transection was complete and that the labeled RGCs represent regenerating axons that traversed the site of transection and not merely fibers that escaped the experimental injury.

The photomicrographs in Figure 4 further verify that regrowth has occurred. In nerves treated with control medium
10 (E) no labeled fibers could be seen distal to the site of HRP application. In nerves treated with SS monocytes (A-D) labeled fibers were seen emerging from the proximal part of the nerve, crossing the site of transection (ST) and extending distally. Structures resembling growth cones (gc)
15 were observed at the tips of these labeled fibers.

6.2.3 AXONAL REGENERATION AFTER TREATMENT WITH MONOCYTES STIMULATED WITH RAT SCIATIC NERVE SEGMENTS FOR VARIOUS INTERVALS

To study the capacity of monocytes to promote axonal
20 regeneration after stimulation for various intervals with sciatic nerve segments, rats were subjected to optic nerve injury and treated at the time of injury with 5×10^3 monocytes cultured with rat sciatic nerve segments for two hours (2h), twelve hours (12h) or seventeen hours (17h). The
25 number of labeled RGCs in individual rats from each treatment group is shown in Figure 5 as a percentage of RGCs labeled in normal optic nerves. Monocytes showed an enhanced capacity to promote axonal regeneration after culture with sciatic
30 nerve segments for each interval tested.

6.2.4 AXONAL REGENERATION AFTER TREATMENT WITH MONOCYTES STIMULATED WITH RAT OR MOUSE SCIATIC NERVE SEGMENTS

To compare the ability of sciatic nerve segments derived from rat and mouse to stimulate the capacity of monocytes to
35 promote axonal regeneration, rats were subjected to optic nerve transection and treated at the time of injury with $5 \times$

10³ rat monocytes cultured for 24 hours either with 1-8 segments of rat sciatic nerve (RAT) or with 2-16 segments of mouse sciatic nerve (MOUSE). The number of labeled RGCs in individual rats from each treatment group is shown in Figure 5 6 as a percentage of RGCs labeled in normal optic nerves. Both rat and mouse sciatic nerve stimulated the capacity of monocytes to promote axonal regeneration.

6.2.5 PHAGOCYTTIC ACTIVITY OF MONOCYTES
FOLLOWING CULTURE WITH SEGMENTS
OF RAT SCIATIC NERVE

10

Rat monocytes were suspended at 2.5×10^5 cells in 1 ml DCCM-1 medium and were cultured for 2-24 hours without further additions (CONTROL), with 1 segment of rat sciatic nerve (1SS), with 2 segments of rat sciatic nerve (2SS), or 15 with 4 segments of rat sciatic nerve (4SS).

The phagocytic activity of the 2SS and 4SS preparations after 2 hours in culture is shown in Figure 7 relative to the phagocytic activity of CONTROL monocytes. After culture for 2 hours with two segments of sciatic nerve, the monocytes 20 showed increased phagocytic activity; after culture for 2 hours with four segments of sciatic nerve, the monocytes showed a greater increase in phagocytic activity.

The phagocytic activity of the 1SS and 4SS preparations after 24 hours in culture is shown in Figure 8 relative to 25 the phagocytic activity of CONTROL monocytes. After culture for 24 hours with one segment of sciatic nerve, the monocytes showed increased phagocytic activity; after culture for 24 hours with four segments of sciatic nerve, the increase in phagocytic activity was even greater. The 4SS preparation 30 showed a greater increase in phagocytic activity after 24 hours than after 2 hours.

6.2.6 PHAGOCYTTIC ACTIVITY OF MONOCYTES
FOLLOWING CULTURE WITH SEGMENTS
OF RAT OPTIC NERVE

35

Rat monocytes were suspended at 2.5×10^5 cells in 1 ml DCCM-1 medium and were cultured for 2-24 hours without further additions (CONTROL) or with 4 segments of rat optic

nerve (4OS). The phagocytic activity of the 4OS preparations after 2 hours in culture is shown in Figure 9 relative to the phagocytic activity of CONTROL monocytes. After culture for 2 hours with four segments of optic nerve, the monocytes showed a decrease in phagocytic activity.

The phagocytic activity of the 4OS preparations after 24 hours in culture is shown in Figure 10 relative to the phagocytic activity of CONTROL monocytes. After culture for 24 hours with four segments of optic nerve, the monocytes showed a decrease in phagocytic activity similar to that seen after 2 hours.

6.2.7 PHAGOCYTIC ACTIVITY OF MONOCYTES FOLLOWING CULTURE WITH SCIATIC NERVE SEGMENTS IN THE PRESENCE OF OPTIC NERVE-CONDITIONED MEDIUM

Optic nerve conditioned medium was prepared by culturing 10 segments of rat optic nerve for 2 hours in 1 ml DCCM-1 medium. While fresh DCCM-1 medium is protein-free, the optic nerve conditioned medium contained protein. Rat monocytes were suspended at 2.5×10^5 cells in 1 ml DCCM-1 medium and were cultured for 24 hours with 1-6 segments of rat sciatic nerve without further additions (0) or with optic nerve conditioned medium at a total protein concentration of 10 $\mu\text{g/ml}$ (10), 1 $\mu\text{g/ml}$ (1) or 0.1 $\mu\text{g/ml}$ (0.1).

Figure 11 presents the phagocytic activity of monocytes cultured with sciatic nerve in the presence of optic nerve conditioned medium relative to the phagocytic activity of monocytes cultured with sciatic nerve in the absence of optic nerve conditioned medium. Addition of optic nerve conditioned medium attenuated the enhancement in phagocytic activity caused by culture with sciatic nerve. This attenuation was most marked in the preparation that received 0.1 $\mu\text{g/ml}$ optic nerve conditioned medium.

6.3 DISCUSSION

These examples demonstrate that monocytes administered at a site of CNS injury promoted axonal regeneration. All

monocytes tested were effective at promoting axonal regeneration. However, monocytes were stimulated (i.e., showed an enhanced capacity to promote axonal regeneration) by culture with a nerve segment, especially with a segment of a peripheral nerve, e.g. sciatic nerve from rat or mouse. This stimulation was evident after all periods of culture tested, i.e. from 2-24 hours. For treating a total transection of a rat optic nerve, which contains about 10^5 nerve fibers, optimal results were obtained by administering about 5×10^3 monocytes. However, every dose tested showed a beneficial effect on axonal regeneration.

These examples also demonstrate that monocytes show increased phagocytic activity after culture with one or more segments of sciatic nerve. Thus, measurement of phagocytic activity provides a rapid and efficient method of screening tissues and cells for their capacity to stimulate monocytes to promote axonal regeneration.

The present invention is not to be limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All publications cited herein are incorporated by reference in their entirety.

30

35

WHAT IS CLAIMED IS:

1. A method of promoting axonal regeneration in the central nervous system (CNS) of a mammal, comprising: administering
5 allogeneic mononuclear phagocytes into the CNS at or near a site of injury or disease.
2. The method according to claim 1, in which said allogeneic mononuclear phagocytes are cultured prior to the
10 step of administering.
3. The method according to claim 1, in which, prior to the step of administering, said allogeneic mononuclear phagocytes are cultured together with at least one stimulatory tissue,
15 with stimulatory cells, with medium conditioned by at least one stimulatory tissue, with medium conditioned by stimulatory cells, or with medium to which at least one stimulatory biologically active agent has been added.
- 20 4. The method according to claim 3, in which the step of culturing said allogeneic mononuclear phagocytes is performed in one or more Teflon bags.
5. The method according to claim 3, in which said
25 allogeneic mononuclear phagocytes are cultured together with dermis prior to the step of administering.
6. The method according to claim 3, in which, prior to the step of administering, said allogeneic mononuclear phagocytes
30 are cultured in medium to which has been added neurotrophic factor 3 (NT-3), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or transforming growth factor- β (TGF- β).
- 35 7. The method according to claim 1, in which said allogeneic mononuclear phagocytes are allogeneic monocytes.

8. The method according to claim 7, in which said allogeneic monocytes are cultured prior to the step of administering.

5 9. The method according to claim 7, in which said allogeneic monocytes are autologous monocytes.

10. The method according to claim 9, in which said autologous monocytes are cultured prior to the step of
10 administering.

11. The method according to claim 1, in which said allogeneic mononuclear phagocytes are autologous mononuclear phagocytes.

15

12. The method according to claim 11, in which said autologous mononuclear phagocytes are cultured prior to the step of administering.

20 13. The method according to claim 1, in which said allogeneic mononuclear phagocytes are allogeneic monocytes or allogeneic macrophages.

14. The method according to claim 1, in which said
25 allogeneic mononuclear phagocytes are allogeneic dendritic cells.

15. The method according to claim 1, in which, prior to the step of administering, said allogeneic mononuclear phagocytes
30 are cultured together with at least one nerve segment or with medium conditioned by at least one nerve segment.

16. The method according to claim 15, in which said nerve segment is a segment of a peripheral nerve.

35

17. The method according to claim 15, in which said nerve segment is a segment of an allogeneic peripheral nerve.

18. A pharmaceutical composition for promoting axonal regeneration in the central nervous system (CNS) of a mammal, comprising:

- 5 (a) allogeneic mononuclear phagocytes that have been cultured together with at least one nerve segment or with medium conditioned by at least one nerve segment; and
- (b) a pharmaceutically acceptable carrier.

10 19. The pharmaceutical composition according to claim 18, in which said nerve segment is a segment of a peripheral nerve.

20. The pharmaceutical composition according to claim 19, in which said nerve segment is a segment of an allogeneic
15 peripheral nerve.

21. The pharmaceutical composition according to claim 18, in which said allogeneic mononuclear phagocytes are allogeneic monocytes.

20

22. The pharmaceutical composition according to claim 21, in which said nerve segment is a segment of a peripheral nerve.

23. The pharmaceutical composition according to claim 21, in
25 which said allogeneic monocytes are autologous monocytes.

24. The pharmaceutical composition according to claim 23, in which said nerve segment is a segment of a peripheral nerve.

30 25. The pharmaceutical composition according to claim 18, in which said allogeneic mononuclear phagocytes are autologous mononuclear phagocytes.

26. The pharmaceutical composition according to claim 25, in
35 which said nerve segment is a segment of a peripheral nerve.

27. A pharmaceutical composition for promoting axonal regeneration in the central nervous system (CNS) of a mammal, comprising:

- 5 (a) allogeneic mononuclear phagocytes that have been cultured together with at least one stimulatory tissue, with stimulatory cells, with medium conditioned by at least one stimulatory tissue or by stimulatory cells, or with medium to which has been added at least one stimulatory biologically
10 active agent; and
(b) a pharmaceutically acceptable carrier.

28. A method of detecting stimulatory activity comprising:

- 15 (a) culturing mononuclear phagocytes together with at least one tissue or with at least one type of cell, or with medium to which has been added at least one biologically active agent; and
(b) measuring the phagocytic activity of said
20 mononuclear phagocytes after the step of culturing.

25

30

35

1/11




FIG.1

2/11




FIG.2

3 / 11

FIG.3A



50μm

FIG.3B

FIG.4A



FIG.4B



FIG.4C



FIG.4D



FIG.4E



5/11




FIG.5

6/11




FIG.6

7/11




FIG.7

8/11




FIG.8

9/11




FIG.9

10/11




FIG.10

11/11




FIG.11

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/14578

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 63/00; A61K 35/12, 35/30; C12N 1/00

US CL : 424/93.7, 520, 570; 435/948

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.7, 520, 570; 435/948

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHAMAK et al. Brain Macrophages Stimulate Neurite Growth and Regeneration by Secreting Thrombospondin. Journal Neuroscience Research, 1994, Vol. 38, pages 221-233. See entire document.	1-28
Y	DAVID et al. Macrophages Can Modify the Nonpermissive Nature of the Adult Mammalian Central Nervous System. Neuron. 1990, Vol. 5, pages 463-469. See entire document.	1-28
Y	PERRY et al. Role of Macrophages in Peripheral Nerve Degeneration and Repair. BioEssays, June 1992, Vol. 14, No. 6, pages 401-406. See entire document.	1-28

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

07 NOVEMBER 1996

Date of mailing of the international search report

26 NOV 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JHUNG-WON COLBY, PH.D.

Telephone No. (703) 308-0196